Novartis Sues Noven Over Generic Dementia Patch

Law360, New York (January 31, 2014, 3:27 PM EST) -- Novartis AG hit Hisamitsu Pharmaceutical Co. Inc. and subsidiary Noven Pharmaceuticals Inc. with a suit in Delaware federal court Thursday, claiming Noven’s proposed generic version of the Exelon patch, used to treat dementia, infringes patents covering the drug.

According to the Swiss pharmaceutical giant, Japan-based Hisamitsu and two Noven units’ planned 13.3 milligram drug containing the active ingredient rivastigmine and used to treat dementia infringes U.S. Patent Nos. 6,316,023 and 6,335,031, patents jointly owned by Novartis and German transdermal patch specialist LTS Lohmann Therapie-Systeme AG....
To view the full article, register now.